Grisnilimab
Based on 1 Customer Validation
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.43%
- CAS 番号: 2367001-70-3
- 分子量:146.39 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Mouse IgG2a
Human
CD7
Grisnilimab (2.5 μg/mL) specifically binds to human lymphoid tissues (T zone pattern) and scattered T lymphocytes, and shows no binding activity to other tested normal human tissues[1].
Grisnilimab (3 μL of 1 mg/mL solution; 30 min) binds to the CD7 antigen on the surface of peripheral blood mononuclear cells from rhesus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2a-lambda
ELISA, FACS, Functional assay
-
Immobilized Human CD7 Protein (His Tag) can bind Grisnilimab. The EC50 for this effect is 22.65 ng/mL.
化学情報
-
CAS 番号 2367001-70-3
-
性状 Liquid
-
分子量 146.39 kDa
-
Color Colorless to light yellow
-
SMILES
[Grisnilimab]
-
別名
WT1
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)